BACKGROUND: Rheumatoid arthritis patients are at increased risk for periprosthetic joint infection after arthroplasty. The reason is multifactorial. Nasal colonization with Staphylococcus aureus is a modifiable risk factor; carriage rates in RA patients are unknown. The goal of this study is to determine the S aureus nasal carriage rates of RA patients on biologics, RA patients on traditional disease-modifying anti-rheumatic drugs (DMARDs), and osteoarthritis. METHODS: Consecutive patients with RA on biologics (±DMARDs), RA on non-biologic DMARDs, or OA were prospectively enrolled from April 2017 to May 2018. One hundred twenty-three patients were determined necessary per group to show a difference in carriage rates. Patients underwent a nasal swab and answered questions to identify additional risk factors. S aureus positive swabs were further categorized using spa typing. Logistic regression evaluated the association with S aureus colonization between the groups after controlling for known risk factors. RESULTS: RA patients on biologics, 70% of whom were on DMARDs, had statistically significant increase in S aureus colonization (37%) compared to RA on DMARDs alone (24%), or OA (20%) (P = .01 overall). After controlling for glucocorticoids, antibiotic use, recent hospitalization, and diabetes, RA on biologics had a significant increased risk of S aureus nasal colonization (Odds ratio 1.80, 95% confidence interval 1.00-3.22, P = .047). CONCLUSION: S aureus colonization risk was increased for RA on biologics compared to RA not on biologics and OA. Nasal S aureus carriage increases the risk of surgical site infection; this modifiable risk factor should be addressed prior to total joint arthroplasty for this higher risk patient group.
BACKGROUND:Rheumatoid arthritispatients are at increased risk for periprosthetic joint infection after arthroplasty. The reason is multifactorial. Nasal colonization with Staphylococcus aureus is a modifiable risk factor; carriage rates in RA patients are unknown. The goal of this study is to determine the S aureus nasal carriage rates of RA patients on biologics, RA patients on traditional disease-modifying anti-rheumatic drugs (DMARDs), and osteoarthritis. METHODS: Consecutive patients with RA on biologics (±DMARDs), RA on non-biologic DMARDs, or OA were prospectively enrolled from April 2017 to May 2018. One hundred twenty-three patients were determined necessary per group to show a difference in carriage rates. Patients underwent a nasal swab and answered questions to identify additional risk factors. S aureus positive swabs were further categorized using spa typing. Logistic regression evaluated the association with S aureus colonization between the groups after controlling for known risk factors. RESULTS: RA patients on biologics, 70% of whom were on DMARDs, had statistically significant increase in S aureus colonization (37%) compared to RA on DMARDs alone (24%), or OA (20%) (P = .01 overall). After controlling for glucocorticoids, antibiotic use, recent hospitalization, and diabetes, RA on biologics had a significant increased risk of S aureus nasal colonization (Odds ratio 1.80, 95% confidence interval 1.00-3.22, P = .047). CONCLUSION: S aureus colonization risk was increased for RA on biologics compared to RA not on biologics and OA. Nasal S aureus carriage increases the risk of surgical site infection; this modifiable risk factor should be addressed prior to total joint arthroplasty for this higher risk patient group.
Authors: Beverly K Johnson; Susan M Goodman; Michael M Alexiades; Mark P Figgie; Ryan T Demmer; Lisa A Mandl Journal: J Rheumatol Date: 2013-04-01 Impact factor: 4.666
Authors: Jennifer Brown; Chin-Shang Li; Mauro Giordani; Kiarash Shahlaie; Eric O Klineberg; Joanna R Tripet-Diel; Marie S Ihara; Stuart H Cohen Journal: Surg Infect (Larchmt) Date: 2015-06-26 Impact factor: 2.150
Authors: Michael D George; Joshua F Baker; Jesse Yenchih Hsu; Qufei Wu; Fenglong Xie; Lang Chen; Huifeng Yun; Jeffrey R Curtis Journal: Arthritis Care Res (Hoboken) Date: 2017-11-02 Impact factor: 4.794
Authors: Stefano Bassetti; Sarah Wasmer; Paul Hasler; Thomas Vogt; Danica Nogarth; Reno Frei; Andreas F Widmer Journal: J Rheumatol Date: 2005-11 Impact factor: 4.666
Authors: Susan M Goodman; Vivian P Bykerk; Edward DiCarlo; Ryan W Cummings; Laura T Donlin; Dana E Orange; Annie Hoang; Serene Mirza; Michael McNamara; Kayte Andersen; Susan J Bartlett; Jackie Szymonifka; Mark P Figgie Journal: J Rheumatol Date: 2018-03-15 Impact factor: 4.666
Authors: J A Kluytmans; J W Mouton; E P Ijzerman; C M Vandenbroucke-Grauls; A W Maat; J H Wagenvoort; H A Verbrugh Journal: J Infect Dis Date: 1995-01 Impact factor: 5.226
Authors: James B Galloway; Louise K Mercer; Alison Moseley; William G Dixon; Andrew P Ustianowski; Matthew Helbert; Kath D Watson; Mark Lunt; Kimme L Hyrich; Deborah Pm Symmons Journal: Ann Rheum Dis Date: 2012-04-24 Impact factor: 19.103
Authors: J B Galloway; K L Hyrich; L K Mercer; W G Dixon; A P Ustianowski; M Helbert; K D Watson; M Lunt; D P M Symmons Journal: Ann Rheum Dis Date: 2011-07-21 Impact factor: 19.103
Authors: Thomas K Fehring; Keith A Fehring; Angela Hewlett; Carlos A Higuera; Jesse E Otero; Aaron J Tande Journal: J Bone Joint Surg Am Date: 2020-07-15 Impact factor: 6.558